Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare giant.

| More on:
Shot of a young scientist looking stressed while conducting medical research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are trading at $276.60 on Thursday, up 0.09% at the time of writing.

This ASX 200 healthcare giant has strong broker support at the moment.

Many major brokerage firms have a buy rating on CSL and 12-month share price targets of $330 to $345.

But boutique investment management firm, Firetrail says it has lost confidence in CSL shares.

Firetrail reduced its holding in its Australian High Conviction Fund significantly last year.

In a recent note, Firetrail said CSL was one of its largest positions in the fund in December 2023.

Today, the fund is underweight in CSL.

Firetail said:

Today our position is well below index weight due to our loss of confidence in the medium-term margin improvement story playing out as we had initially forecast.

The entry of new competition and a couple of trial hiccups have eroded what was previously a compelling earnings story.

What about the CSL share price?

Firetail made no comment about the performance of the CSL share price.

But as long-term investors know, CSL has not been able to maintain any price growth since the pandemic.

In early 2020, the CSL share price was about $300. Five years later, it's trading 7.8% lower than that.

Over the past couple of years, many brokers have predicted that CSL shares will break through $300 again and, most importantly, stay there.

Back in July 2023, 12 brokers had price targets of $313 to $340 for the end of FY24 that did not eventuate.

CSL shares closed at $295.21 on the last day of trading for FY24.

The ASX 200 biotech finished the calendar year 2024 at $281.58 apiece, down 1.77% over the 12 months.

The stock did rise to a 52-week high of $313.55 in July, but it could not maintain this level. After the company released its FY24 results in August, a painful second-half decline began.

CSL vastly underperformed the benchmark S&P/ASX 200 Index (ASX: XJO), which rose 7.49% last year.

Long-term investors in CSL aren't really used to this sort of sluggishness in the share price.

The stock has an amazing history of reasonably steady long-term growth but it has struggled to stay above $300 per share for any length of time since the pandemic.

Check out the chart below. The CSL share price has moved in a pretty tight band between 2020 and 2024.

Now, take a look at this second chart, which documents the stock's long-term growth trajectory.

It paints a picture of reliable and gradual share price growth prior to the pandemic in 2020.

What will happen to the CSL share price in 2025?

As we mentioned earlier, many brokers maintain a positive outlook for the CSL share price in 2025.

But it's interesting to note that CommSec downgraded the consensus recommendation on CSL shares last month from strong buy to moderate buy. The rating changed on 17 December.

Of the 15 analysts rating the stock on CommSec, nine say it's a strong buy, four say moderate buy, and two say hold.

You can check out specific broker ratings and price targets for the end of 2025 here.

What's next for CSL?

CSL will release its FY25 half-year results and announce its interim dividend on 11 February.

More on Broker Notes

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 30% to 40%

Analysts are tipping these shares to generate big returns over the next 12 months.

Read more »

A female worker in a hard hat smiles in an oil field.
Broker Notes

Buy BHP and this ASX 200 share next week

Here are a couple of shares that Bell Potter rate highly this month.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Broker Notes

Why did this $1 billion ASX 300 stock just crash 10%?

This stock isn't having a good finish to the week. What's going on?

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Blue Chip Shares

Is it too late to buy this $33 billion ASX 200 stock?

Do analysts think this popular stock can deliver good returns for investors? Let's find out.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Broker Notes

5 ASX All Ords shares upgraded to 'strong buy' consensus ratings

Brokers upgraded their ratings on these ASX All Ords stocks last month.

Read more »

A couple cheers as they sit on their lounge looking at their laptop and reading about the rising Redbubble share price
Broker Notes

2 more of the best ASX 200 shares to buy in February

The broker is feeling very bullish about these shares. Let's see what it is saying.

Read more »